Your browser doesn't support javascript.
loading
Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy.
Paula, Bruno de; Crocamo, Susanne; de Sousa, Carlos Augusto Moreira; Valverde, Priscila; Rezende, Fabiana; Abdelhay, Eliana.
Afiliação
  • Paula B; Núcleo de Pesquisa Clínica, Hospital do Cancer III, Instituto Nacional de Câncer -, Rio de Janeiro 20560-121, Brazil.
  • Crocamo S; School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guilford GU2 7XH, UK.
  • de Sousa CAM; Núcleo de Pesquisa Clínica, Hospital do Cancer III, Instituto Nacional de Câncer -, Rio de Janeiro 20560-121, Brazil.
  • Valverde P; Faculdade de Ciências Medicas, UERJ-Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20551-030, Brazil.
  • Rezende F; Divisão de Patologia, COAS, Instituto Nacional de Câncer-INCA, Rio de Janeiro 20220-400, Brazil.
  • Abdelhay E; Divisão de Patologia, COAS, Instituto Nacional de Câncer-INCA, Rio de Janeiro 20220-400, Brazil.
Int J Mol Sci ; 25(11)2024 May 27.
Article em En | MEDLINE | ID: mdl-38892013
ABSTRACT
The intrinsic subtype of triple-negative breast cancer (TNBC) is based on genomic evaluation. In this study, we report the survival and pathological complete response (pCR) rates of TNBC patients subtyped by IHC and treated with neoadjuvant chemotherapy (NACT). A retrospective cohort of 187 TNBC patients who received NACT between 2008 and 2017 was used, and IHC subtyping was performed on biopsy specimens before chemotherapy. The subtyping revealed predominantly basal-like tumors (IHC-BL, 61%), followed by basal-like immune-suppressed tumors (IHC-BLIS, 31%), mesenchymal tumors (12.5%), luminal androgen receptor tumors (IHC-LAR, 12%), and basal-like immune-activated tumors (IHC-BLIA, 10.9%). The pCR rate varied among subtypes, with IHC-BLIA showing the highest (30.0%) and IHC-LAR showing the lowest (4.5%). IHC-BLIS led in recurrence sites. Overall and disease-free survival analyses did not show significant differences among subtypes, although IHC-BLIA demonstrated a trend toward better survival, and IHC-mesenchymal, worse. Patients who achieved pCR exhibited significantly better disease-free survival and overall survival than non-responders. This study underscores the potential of IHC-based subtyping in TNBC management, highlighting distinct response patterns to neoadjuvant chemotherapy and potential implications for treatment strategies. Further research is warranted to validate these findings and explore tailored therapeutic approaches for specific TNBC subtypes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imuno-Histoquímica / Terapia Neoadjuvante / Neoplasias de Mama Triplo Negativas Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imuno-Histoquímica / Terapia Neoadjuvante / Neoplasias de Mama Triplo Negativas Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil